#news #biotech AB Science trumpets phase 3 ALS data, but investors seem unmoved

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: AB Science trumpets phase 3 ALS data, but investors seem unmoved .AB Science says its drug candidate masitinib has slowed down progression in a late-stage trial, but its checkered development history means the reaction is muted.

from FierceBiotech: Biotech http://ift.tt/2ryFLfN